Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Single Nucleotide Polymorphism (SNP) Genotyping Market Growth From $14.69 Billion In 2026 To $29.74 Billion By 2030 At A CAGR Of 19.3%
The market for single nucleotide polymorphism (snp) genotyping has seen significant expansion lately, projected to expand from $12.34 billion in 2025 to $14.69 billion in 2026, indicating a compound annual growth rate (CAGR) of 19.1%. This expansion during the past period was propelled by factors such as restricted early-stage genotyping technologies, increasing research requisitions, the substantial expense associated with genomic examinations, escalating partnerships among research facilities, and the early integration within pharmacogenomics applications.
The market for single nucleotide polymorphism (SNP) genotyping is poised for substantial expansion, projecting a value of $29.74 billion by 2030, driven by an impressive compound annual growth rate of 19.3%. This accelerated growth over the projected timeframe is largely fueled by advancements in high-throughput SNP platforms, the expanding application of SNP genotyping in personalized medicine, its synergistic integration with artificial intelligence for advanced predictive analytics, increased utilization within clinical diagnostics, and the burgeoning use in agricultural genomics. Key developments anticipated during this period include deeper integration with pharmacogenomics, a growing emphasis on predicting disease risk, expanded applications in both agriculture and animal breeding sectors, the continued adoption of microarray-based genotyping methodologies, and a notable increase in point-of-care SNP testing solutions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12569&type=smp
Single Nucleotide Polymorphism (SNP) Genotyping Market Growth Drivers And Industry Catalysts
The expanding challenge posed by long-term health issues is poised to stimulate advancement within the single nucleotide polymorphism (SNP) genotyping market. Chronic health conditions, characterized by their persistence for a year or more and requiring ongoing medical attention or limiting daily life activities, are becoming more prevalent. SNP genotyping plays a crucial role in pinpointing genetic susceptibilities and advancing tailored healthcare approaches, especially as these chronic diseases become more widespread. To illustrate, data from the Centers for Disease Control and Prevention (CDC), a federal entity in the United States, indicated that in 2023, a significant portion of American adults, around 194 million or 76.4%, dealt with at least one chronic condition. This prevalence varied across age groups, affecting 59.5% of younger adults, 78.4% of middle-aged adults, and an overwhelming 93.0% of older adults. Consequently, the escalating impact of chronic diseases is a key factor fueling the expansion of the market for single nucleotide polymorphism (SNP) genotyping technologies.
Single Nucleotide Polymorphism (SNP) Genotyping Market Segment Analysis And Revenue Opportunities
The single nucleotide polymorphism (snp) genotyping market covered in this report is segmented –
1) By Product: Consumables, Instruments, Services
2) By Technology: TaqMan SNP Genotyping, Mass Array SNP Genotyping, SNP Gene Chip Arrays, Other Technologies
3) By Application: Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals And Pharmacogenomics, Agricultural Biotechnology, Other Applications
Subsegments:
1) By Consumables: Reagents And Kits, DNA Probes, Microarrays
2) By Instruments: SNP Genotyping Platforms, Sequencers, PCR Machines
3) By Services: SNP Genotyping Services, Data Analysis Services, Consultation Services
#Single Nucleotide Polymorphism (SNP) Genotyping Market Trends Influencing Long-Term Demand
Corporations at the forefront of the single nucleotide polymorphism (SNP) genotyping sector are actively creating biomarkers beneficial for identifying coronary heart disease, aiming to boost their market earnings. These SNP biomarkers for coronary heart disease (CHD) detection represent distinct genetic alterations, pinpointed via genomic studies, which correlate with a heightened predisposition or vulnerability to the condition. As an illustration, in February of 2023, Cardio Diagnostics, a biotechnology firm situated in the United States, introduced PrecisionCHD. This innovative, AI-powered blood test integrates both epigenetic markers, specifically DNA methylation, and genetic markers, namely single nucleotide polymorphisms, to facilitate CHD detection. The employed machine-learning algorithm achieves a diagnostic sensitivity exceeding 75% across both sexes, offering a non-invasive method for collecting blood samples either in a clinical setting or at home, thereby circumventing the need for conventional diagnostic procedures like stress tests and ensuring an objective assessment solely based on biomarkers, independent of subjective patient self-reporting.
Single Nucleotide Polymorphism (SNP) Genotyping Market Leading Players Shaping Industry Direction
Major companies operating in the single nucleotide polymorphism (snp) genotyping market are Thermo Fischer Scientific Inc, Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc, Eurofins Genomics LLC, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Qiagen N.V, Sigma-Aldrich Corporation, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc, LGC Ltd, Sequenom Inc, Fluidigm Corporation, Oxford Gene Technology, Affymetrix Inc, PREMIER Biosoft International Inc, Rubicon Genomics, Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc
Access The Complete Single Nucleotide Polymorphism (SNP) Genotyping Market Report:
Single Nucleotide Polymorphism (SNP) Genotyping Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
